Anticancer activity of tyrosine kinase TrkA receptors antagonist GK-1 in experiment on mice with mammary gland adenocarcinoma Ca755

The aim of this study was to evaluate the effect of original tyrosine kinase TrkA antagonist GK-1 on tumor growth, median lifespan and hematological parameters in experiment on female mice C57Bl/6 with mammary gland adenocarcinoma Ca755. 14-day intraperitoneal administration of GK-1 at a dose of 10 mg/kg resulted in a significant tumor growth inhibition (TGI) on the 9th, 15th, and 21st day of adenocarcinoma Ca755 development. TGI on the 21st day was 60 %. Administration of GK-1 at doses of 1 mg/kg and 10 mg/kg significantly increased median lifespan of experimental animals by 53 % and 47% respectively. Median lifespan was calculated using the Kaplan-Meier survival analysis. Median lifespan of active control group was 18 days, in groups that received GK-1 at doses of 1 mg/kg and 10 mg/kg median lifespan was 30 days. Hematological parameters of experimental animals were not altered by administration of GK-1. Double injection of the doxorubicin on the 2nd and the 4th day of tumor development at dose of 4 mg/kg resulted in TGI by 73% on the 21st day of experiment, increase in lifespan was 58% and median lifespan was 31 days. Our data show that further investigation of the antitumor activity of GK-1 may bring promising results.